This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The ADAPT study will evaluate the safety and effectiveness of the Calibreye surgical system in up to 70 patients with refractory glaucoma.

McDonald is clinical professor of ophthalmology at both NYU Langone Medical Center, New York, New York and Tulane University Health Sciences Center, New Orleans, Louisiana, and in practice with OCLI ...

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, ...

Haller, MD, as new chief executive officer ...

PA5108 is a rod-shaped, biodegradable micro implant designed to significantly reduce IOP in patients with primary open-angle ...

Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure of ENCELTO, the ...

New research reveals that increased physical activity significantly slows visual field loss in glaucoma patients, ...

AI plays a crucial role in the segmentation of diagnostic imaging, another area where precision is paramount. This platform ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...